244 related articles for article (PubMed ID: 36166198)
1. B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
McLachlan T; Matthews WC; Jackson ER; Staudt DE; Douglas AM; Findlay IJ; Persson ML; Duchatel RJ; Mannan A; Germon ZP; Dun MD
Mol Cancer Res; 2022 Dec; 20(12):1711-1723. PubMed ID: 36166198
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
3. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
4. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
[TBL] [Abstract][Full Text] [Related]
5. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
8. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.
Sandhu SK; Volinia S; Costinean S; Galasso M; Neinast R; Santhanam R; Parthun MR; Perrotti D; Marcucci G; Garzon R; Croce CM
Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20047-52. PubMed ID: 23169640
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
10. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
Lu X; Fernando TM; Lossos C; Yusufova N; Liu F; Fontán L; Durant M; Geng H; Melnick J; Luo Y; Vega F; Moy V; Inghirami G; Nimer S; Melnick AM; Lossos IS
Blood; 2018 Nov; 132(19):2026-2039. PubMed ID: 30082494
[TBL] [Abstract][Full Text] [Related]
11. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
[TBL] [Abstract][Full Text] [Related]
12. CD137L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy.
Ding Z; Quast I; Yan F; Liao Y; Pitt C; O-Donnell K; Robinson MJ; Shi W; Kallies A; Zotos D; Tarlinton DM
Immunol Cell Biol; 2022 Oct; 100(9):705-717. PubMed ID: 35916066
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
14. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
16. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
17. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
[TBL] [Abstract][Full Text] [Related]
18. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
19. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
